Exclusive distribution agreement covers plant extract products for the complementary medicine segment  

Brenntag, the global market leader in chemicals and ingredients distribution, today announced the signing of the distribution agreement with Greenyn Biotechnology, covering a range of innovative and scientifically proven solutions such as Insumate® bitter melon peptides, Antromax® Antrodia Cinnamomea and Zymologist® fermented fruit and vegetable extract.

Greenyn Biotechnology is an international company headquartered in Taichung, Taiwan specializing in dietary supplements. Over the last decade, Greenyn Biotechnology has obtained multiple international food quality system certifications, such as FSSC 22000, ISO 22000, HACCP, TQF, HALAL, ISO/IEC 17025, and GMP.

“We are excited to announce our strategic collaboration with Brenntag to serve the surge in the consumption of complementary medicine as consumers in the Asia Pacific prioritize holistic approaches to health and well-being. By leveraging the combined prowess of both companies’ strengths in product development and marketing and with Brenntag’s extensive distribution network, we can cater to evolving consumer preferences with innovative formulations, personalized supplements, and tailored health solutions,” said Chia-Fen Wu, Chairman, Greenyn Biotechnology.

Romain Girard, Regional President, Pharma Asia Pacific, Brenntag Specialties said, “Brenntag prioritizes the prevention of chronic diseases, and our partnership with Greenyn Biotechnology signifies a concerted effort towards enhancing access to high-quality and scientifically proven complementary medicines for the Asian population. Backed by the robust endorsement of the US FDA, these medicines hold immense potential in promoting holistic well-being. We eagerly anticipate this collaboration, rooted in principles of excellence, innovation, and a shared commitment to advancing healthcare.”

About Greenyn Biotechnology

Greenyn Biotech is a renowned international dietary supplement company, distinguished for its pioneering approach to developing innovative supplements imbued with distinctive Taiwanese characteristics and global appeal. With an unwavering commitment to excellence, Greenyn Biotech has devoted significant efforts to conducting rigorous clinical trials and exploring human applications for its health ingredients. This dedication has been duly recognized through numerous international awards and achievements, solidifying Greenyn Biotech’s position as a trailblazer in the field of dietary supplements.

Notably, Insumate® stands out as a patented bitter melon extract, boasting the groundbreaking mcIRBP-19 peptide sequence—a dietary supplement endorsed by the U.S. FDA as a New Dietary Ingredient (NDIN No. 1256) for diabetes management. Equally noteworthy is Antromax®, derived from Antrodia Cinnamomea (NDIN No. 1170), recognized as the world’s foremost and safest Antrodia Cinnamomea product endorsed by the FDA for liver protection. Additionally, Zymologist®, a fermented vegetable and fruit extract renowned for its fiber-rich, low-sugar composition supporting digestive function, represents another flagship product from Greenyn Biotech.

About Brenntag

Brenntag is the global market leader in chemicals and ingredients distribution. The company holds a central role in connecting customers and suppliers of the chemical industry. Headquartered in Essen, Germany, Brenntag has more than 17,700 employees worldwide and operates a network of about 600 sites in 72 countries. In 2023, Brenntag generated sales of 16.8 billion EUR. 

The two global divisions, Brenntag Essentials and Brenntag Specialties, provide a diversified and broad portfolio of industrial and specialty chemicals and ingredients as well as tailor-made application, marketing and supply chain solutions, technical and formulation support, comprehensive regulatory know-how, and digital solutions for a wide range of industries.

Brenntag pursues an ambitious sustainability agenda and is committed to sustainable solutions in its own sector and the industries served. Brenntag shares have been listed on the Frankfurt Stock Exchange since 2010 in the DAX since September 2021. In addition, the Brenntag SE shares are listed in the DAX 50 ESG and DAX ESG Target. For more information, visit www.brenntag.com.